

Ministry of Health

Health Programs and Delivery Division

## Drug Submission Status

Report for July 2025

### Complete Streamlined Multiple-Source Submissions for Future Formulary Listing

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Rivaroxaban	Xarelto	RIVAROXABAN	2.5 mg	tablet	02553368
Sandoz Canada Inc.	Sandoz Tofacitinib	Xeljanz	TOFACITINIB	5 mg	tablet	02551691
Sandoz Canada Inc.	Sandoz Tofacitinib	Xeljanz	TOFACITINIB	10 mg	tablet	02551705

Marcan Pharmaceuticals Inc.	Mar-Dienogest	Visanne	DIENOGEST	2 mg	tablet	02551683
Pharmaris Canada Inc.	PRZ-Metoclopramide	Maxeran	METOCLOPRAMIDE HCl	5 mg	tablet	02548747
Teva Canada Limited	Teva-Doxylamine/Pyridoxine DR	Diclectin	DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE	10 mg / 10 mg	DR tablet	02304503
Sandoz Canada Inc.	Sandoz Tacrolimus XR	Advagraf	TACROLIMUS	0.5 mg	ER capsule	02528592
Sandoz Canada Inc.	Sandoz Tacrolimus XR	Advagraf	TACROLIMUS	1 mg	ER capsule	02528606
Sandoz Canada Inc.	Sandoz Tacrolimus XR	Advagraf	TACROLIMUS	3 mg	ER capsule	02528622
Sandoz Canada Inc.	Sandoz Tacrolimus XR	Advagraf	TACROLIMUS	5 mg	ER capsule	02528630
Laboratoire Riva Inc.	Pantoprazole	Pantoloc	PANTOPRAZOLE SODIUM	40 mg	DR tablet	02431327
Laboratoire Riva Inc.	Riva-Valacyclovir	Valtrex	VALACYCLOVIR	500 mg	tablet	02316447